Immunotherapeutic Potential of Plasmodium Against Cancer by Inducing Immunomodulation by Riaz, Aqsa
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) DOI: 10.7176/ALST 
Vol.70, 2019 
 
8 
Immunotherapeutic Potential of Plasmodium Against Cancer by 
Inducing Immunomodulation 
 
Aqsa Riaz1,3      Awais Ali1,2      Usman Babar2,3,4      Usama Arshad2,3,4      Muhammad Asad Ullah1,3,4 
Ali Usman1,2      Mirza Sabuktgeen Baig1,2      Muhammad Faizan Manzoor1,2      Usama Zahir1,2. 
1.Institute of Molecular Biology and Biotechnology (IMBB), University of Lahore, Pakistan 
2.Centre for Research in Molecular Medicine (CRiMM), University of Lahore, Pakistan 
3.University Institute of Diet and Nutritional Sciences (UIDNS), University of Lahore, Pakistan 
4.Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad 
5.Centre of Advanced Studies, Agriculture and Food Security (CAS-AFS), University of Agriculture, 
Faisalabad, Pakistan 
 
Abstract 
Cancer is one of the most death leading disease across the globe because of the unavailability of innocuous 
treatment strategy for cancer control so far but while having comparative study with malaria, it was found that 
there is some resemblance within the physiological conditions of the body as well as some antagonistic effects. 
Plasmodium is a parasitic microbe that is familiar for causing malaria within the animals and by thorough study, 
the immunotherapeutic potential of this organism was found against cancer as it consists of some tumor-
associated antigens (TAAs) that favors the body in combating tumor by inducing immunomodulation and 
causing certain advantageous physiological changes. 
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Introduction 
Plasmodium is a protozoan that belongs to the genus of parasitic alveolates which feed on their hosts are known 
for their infectious cause i.e. Malaria. Plasmodium is representative of family; Plasmodiidae, Order; 
Haemosporida, Class; Aconoidasida, Phylum; Apicomplexa and Domain’ Eukaryota by its taxonomy and 
characteristics. There are almost 200 species of plasmodium that have been identified so far. The parasite was 1st 
diagnosed and identified over a century ago, in 1880 by Charles Louis Alphonse Laveran within malaria 
patients.[1] Cancer is one of the most fatal health disasters throughout the world. Depending upon the type and 
nature of tumor, it can be benign (Acute or non-cancerous) or malignant (Chronic or cancerous). Term ‘Cancer’ 
is basically coined for malignant tumor that is highly lethal as it metastasize, retains inside body for prolonged 
period and ultimately leads to the death.[2] Lung cancer is the most common among all the cancer types 
throughout the world. According to a survey, it was reported that increment of around 1.8 Million cases was 
recorded per year, similarly, deaths of 1.6 Million cases shows the increased mortality rate due to this disease.[3] 
Different approaches such as chemotherapy, radiotherapy and surgery etc have been invented and improved for 
cancer cure and control but still the prognosis remains dissatisfying. Therefore, the development of 
immunotherapy or therapeutics is mandatory in order to control or getting rid of cancer.[4] 
The development of therapeutic vaccination was the major aspect of immunotherapy that was passively 
induction or elicitation of the host immune system in response to the tumor-associated antigens (TAAs).[5] But 
the recent studies and researches have claimed the presence of some parasites like Plasmodium may play a role 
in getting rid of immunosupression and with the enhanced immune system, it helps in the cancer growth 
inhibition.[6] Hence, the parasites can also be one of the therapeutic approach for cancer treatment in near future. 
It has been reported that the method of immunotherapy was developed in order to cure the lung cancer by 
eliciting the immune response of the patient’s body with the help of some immunostimulants that were specific 
as well as non-specific to tumor antigens like mucin-1 (MUC1) and melanoma-associated antigen-3. As the 
cancer weakens host immunity by causing immunosuppression in body.[7] 
By last century, Malaria was supposed to be very problematic as it causes hyperthermia, high fever, and 
also led to death in several cases due to failure of homeostasis. The etiology of disease was found as presence of 
an intracellular parasite, Plasmodium, that was responsible for causing human malaria parasitic infection.[8] In 
21st century, the clinical significance of this malarial infection has been studied thoroughly and it has been 
reported that the infection is responsible for the enhancement of various immunological processes such as 
proliferation of T-cells, maturation induction in dendritic cells (DC)[9], increased production of Interferon (IFN-
c) and activation of cell mediated immunity that involves Natural killer (NK) cells, NKT-cells and cytotoxic T-
cells.[10] Such fluctuation in the body immune response produces the favorable conditions that are proved to be 
advantageous in confronting different types of the clinical cancers.[11] Clinically, a malarial symptom, 
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hyperthermia, has also been observed as a  significant body condition for combating and treating few cancer 
types.[12] Therefore, the malarial parasite, Plasmodium, due to its clinical importance in cancer treatment has 
been considered as a therapeutic agent. The parasite was analyzed within mouse model and for the confirmation, 
murine lewis lung cancer (LLC) was treated with it. The immunological mechanisms as well as the antitumor 
effects of this therapeutic agent were studied. It was reported that the metastasis and cancer growth was 
controlled by the plasmodium. The antitumor effect was caused due to the induction of dynamic innate and 
adaptive immunity that developed in reponse to the uncontrolled or abnormal neoplastic growth.[13] 
85-90% cases of Hepatocellular Carcinoma (HCC) were reported according to survey out of all the types of 
liver cancers. It is the 3rd most fatal cancer type throughout the world.[14] In 2012, around 782,500 new cases and 
approximately 745,500 deaths due to liver cancer were recorded.[15] At the initial cancer stages, AFP, α-fetal 
protein, from dendritic cells or glypican III (GPC3) derived vaccines were tested and the cellular mediated 
immune response by cytotoxic T-cells was activated in HCC patients. As a result of that, a huge decline in the 
mortality rate was observed.[16] By performing further clinical trials, more encouraging results were examined for 
combating the HCC.[17] 
It has been acknowledged that the tumor growth can be suppressed by some pathogenic infections as they 
comprised of the counter ability.[18] Genomic DNA, haemozoin[19], pathogen-associated molecular patterns 
(PAMPs) and glycosylphosphatidylinositol anchors (GPI)[20] are the major constituents of Plasmodium parasite 
that are usually detected by the host’s innate immune system. Thus, dendritic cells, macrophages, NK-cells, 
NKT-cells, γδ-T-cells, cytotoxic T-cells and helper T-cells are activated at the initial stage of cancer i.e. blood-
stage (erythrocytic stage).[21] Hence, it was reported that the enhancement in the host immune system due to a 
pathogenic infection also confront the antitumor immunity. GPC3 is one of the most significant tumor-associated 
antigens (TAAs) that is related to hepatocellular carcinoma (HCC)  and its cytotoxic T-lymphocytes (CTL) are 
found to be present in both mice and the patients.[22] This TAA, GPC3 Ag was used in the development of 
certain peptide vaccines that showed high survival rate in patients.[16] The application of GPC3-peptide vaccine 
to the patients that have already received radiofrequency ablation (RFA) surgery or therapy showed the 
improvement in their survival rate upto a year.[23] Moreover, chimeric antigen receptor (CAR) T-cells have been 
developed that are targeted by GPC3 antigen in order to get the therapeutics for treatment.[24] It has been reported 
that GPC3 is an ideal TAA for the immunotherapy of  HCC due to its distinct immunological characteristics.[25] 
 
Infection Mechanism of Plasmodium 
Malaria infection is caused in the host by the injection of Plasmodium within the blood stream of host at 
sporozoites stage by the help of female Anopheles mosquito’s bite. The mosquito acts as a vector for this 
infectious agent. Characteristics of Plasmodium species while causing malaria are shown in Table 1. It is 
persumed that a single sporozoite is enough for causing infection in host but the number injected by the 
mosquito while having a meal varies from a few dozens to thousands. By clinical diagnosis of the malaria 
patients, it has been reported that sporozoite load, short incubation period and serious symptoms for malaria are 
caused due to a mosquito bite. The sporozoites stays in blood stream for an hour and then invades liver of 
host.[26] The sporozoites either invades Kuppfer cells of liver, failed to develop themselves in it and die soon or 
they enter hepatocytes and starts to reproduce asexually through ‘Exo-erythrocytic Schizogonic cycle’. 
In liver, trophozoite seems like mono-nucleated round body within host cytosol for the nutrient uptake. 
With the passage of time, it develops and replicates by asexual reproduction and turned into a mature, muti-
nucleated parasite i.e. Schizont. It is approximately 30-70 micrometres in size and doesn’t exhibit any pigment 
due to absence of hemoglobin in hepatocytes. It starts to occupy entire cellular cytoplasm for over a week to two 
and then ultimately release a wide range (2,000-30,000) of merozoites. It is the final stage of the life cycle of 
plasmodium in which the released merozoites starts to invade RBCs. The mechanism is similar in all the 
experimented plasmodium species such as Plasmodium falciparum, Plasmodium ovale, Plasmodium vivax and 
Plasmodium malariae.[27] Two of these species P. Vivax and P. Ovale also shows an additional stage in their life 
cycle in which they stays into liver for a variable time period in latent stage and are known as hypnozoites.[28] 
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Table 1: Characteristics of Malaria Infection in Human Plasmodium Species 
Infection Characteristics P. vivax P. ovale P. malariae P. falciparum 
Pre-erythrocytic Cycle 
Erythrocytic Cycle 
Pre-patent period 
Incubation Period 
No. of Schizont 
Hypozoites 
Average Parasitemia 
Maximum Parasitemia 
Severity of Initial paroxysms 
Typical Symptom Duration 
Maximum Infection Duration 
Anemia 
Other Complications 
8 days 
48 h 
10-13 days 
12-17 days 
~10,000 
+ 
20,000 
50,000 
Moderate 
3-8 weeks 
5-8 years 
Moderate 
- 
9 days 
50 h 
10-14 days 
16-18 days 
~15,000 
+ 
9,000 
30,000 
Mild 
2-3 weeks 
12-20 months 
Mild 
- 
13 days 
72 h 
15-16 days 
18-40 days 
~2,000 
- 
6,000 
20,000 
Moderate 
3-24 weeks 
20-50 years 
Moderate 
Renal 
5-6 days 
48 h 
9-10 days 
9-14 days 
~40,000 
- 
50,000-500,000 
2,500,000 
Severe 
2-3 weeks 
6-17 months 
Severe 
Cerebral 
 
Identification of Tumor-associated Antigens from Plasmodium 
In malaria parasite, Plasmodium falciparum, glycosylphosphatidylinositol (GPI) was examined and reported as a 
tumor-associated antigen (TAA) because of its induction role in proinflammatory responses within host via Toll-
like its receptor (TLR-2) in MyD88 (myeloid Differentiation) mediated signaling pathway.[29] Hemin 
detoxification produces a byproduct within plasmodium i.e. Hemozoin, a biocrystalline substance that regulates 
the activation of immune system of host via TLR-9.[30] Along with certain model antigens, it also showed the 
potent adjuvant effect. A tumor-specific effect or response can be facilitated by inbuilt adjuvant. By taking up 
with a vaccine, this plasmodium component can be an ideal adjuvant as it is performing a function against tumor 
hence, it can also be a TAA for the tumor-specific vaccine development.[31, 32] The TAAs reported so far are 
mentioned in Table 2. 
Table 2: Tumor-associate Antigens (TAA) and their Respective Functions 
TAAs from Plasmodium Functions 
GPI 
Hemozoin 
Induction of Pro-inflammatory Responses 
Activation of Innate Immune System 
Other TAAs 
AFP (α-Fetal Protein) 
CEA (Carcinoembryonic Ag) 
MUC1 (Mucin-1) 
GPC3 (Glypican-3) 
Oncofetal Antigen 
Oncofetal Antigen 
Overexpression in Tumor Cells 
Role in Cell Division and Growth Regulation 
 
Antitumor Activity of Plasmodium against Lewis Lung Cancer 
It was believed that malaria caused by Plasmodium yoelii 17XNL shows some antitumor activity within 
erythrocytic stage hence, an experiment was performed on two groups of mice and the similar number of 
infected as well as plain LLC cells of mice were injected in model organisms for the evaluation of the effect of 
infection over LLC growth and metastasis. It was observed that within the malarial infectious period, the 
suppression in the tumor growth, volume and metastasis was developed while in the mice having just LLC 
healthy cells showed tumor growth. After a month of the inoculation of erythrocytes (both LLC and infected 
LLC), the changes with the passage of time in growth and metastasis were evaluated and it was reported that the 
LLC cells divided and metastasized at constant rate while the rate of growth and metastasis in plasmodium 
infected LLC cells reduced to a negligible amount i.e. 1/10. The trial was conducted on the aggresively 
metastasizing models that were produced by injecting LLC tumor cells.[33]  
The crucial cause of death among the cancer patients is distant metastases.[34] Hence, two different 
treatment strategies (Surgery and malarial infection) were applied together for the verification of anti-metastatic 
activities in host. At the initial stage, primary tumor was removed surgically and after 5 days, plasmodium was 
infected in half of the mice models and rest were left uninfected. The plasmodium infected mice tolerated the 
primary tumor after surgery and survived longer than the other ones. These outcomes represented that the 
malarial parasite, plasmodium, exhibit the capability to counter the late steps of metastasis that usually develops 
in host with the invasion of metastatic tumor cells from the blood stream.[13] 
 
Improvement in LLC Host Physiological Processes by Malaria and their Verification by Tumor Markers 
Malaria is a pathogenic infection that is usually caused by Plasmodium parasite that plays a significant role in 
enhancing the host’s physiological processes against the tumor like cell proliferation, apoptosis and 
angiogenesis.  
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Tumor staining with Ki67, a proliferation marker, was examined within the malarial infected LLC mice 
model and the suppression in the tumor cell proliferation was reported in it. That suppression act as a signaling 
for the apoptosis activation within the tumor cells due to plasmodium presence while no such change was 
observed in LLC mice models. After 17 days, the terminal deoxynucleotidyl transferase-dUTP nick end labeling 
(TUNEL) assay of the tumors was performed. In order to check the effect of proliferation decrease and apoptosis 
increase whether related to vascular pruning in the tumor blood vessels.[35] Similarly, CD31 was also stained 
over the endothelial cells of blood vessels in order to examine the vasculature of the tumor within mice with 
LLC and both (LLC and plasmodium) and the suppression of angiogenesis was observed in the infected group. 
Table 3: Improvements in Host System by Plasmodium Infection 
Improved Physiological Processes by Malaria Improved Immunological Processes by Malaria 
 Tumor Cell Proliferation 
 Apoptosis 
 Angiogenesis 
 DCs Maturation 
 Cytotoxicity Induction in NK-Cells 
 Cell-Mediated Immunity Activation 
 Increased TH1-type Cytokines Production 
 
Mechanism of Plasmodium Antitumor Activity 
The pre-activated antibodies (Ab), non-tumor specific as well as TAA-specific immune responses (Both Cellular 
and Humoral) were suppressed due to tumor growth but recovered with the infection of malaria parasite and 
plays a significant role in inhibition of tumerigenesis at its earlier or initial stage. With the invasion of malaria 
infection within the tumor exhibiting cells/host, a series of innate as well as adaptive immune responses are 
enhanced and induced that act against the tumor. Certain components of plasmodium are pronounced to be of 
purpose while developing a TAA-specific vaccine.[30] 
 
Induction of Adaptive Immunity by Tumor Associated Antigens 
Due to weak immunogenic ability of LLC cells, no potential immune response could be generated by the body. 
The major reason of that is resemblance of neoplastic LLC cells with the normal body cells. Therefore, it is very 
challenging to study and identify the antigen (Ag) specificity that have induced the immune response (IR) within 
the host body containing LLC cells.[36] A recombinant LLC cell line (LLC-MUC1) expressing mucin-1 
glycoprotein was developed for the evaluation of TAA-specific immune responses that were induced by invasion 
of malaria infection.  
For further confirmation of the origin of specificity of induced immune response whether it is TAA or any 
other self-antigen of mouse. A cross-species cell line (LLC-MUC1) was developed by inserting an exogenous 
mucin-1 gene from human into cancerous cell line of mouse. It was reported that the cell line having human 
mucin-1 gene showed greater immunogenecity within mice as compared to the recombinant cell line. Due to the 
clear observation of epitope of human MUC1, it would now be easy to interpret the distinctions in the immune 
responses among different cell lines under observation that were TAA-specific. 
 
Maturation Induction in Dendritic Cells 
There was not much variation observed among the parent LLC-cells and recombinant LLC-MUC1 cells in their 
phenotypic traits as well as growth under both (in vivo and in vitro) conditions. Here, the major role of dendritic 
cells (DCs) was found that was associated with the initiation and maintenance of antigen-specific immunity.[37] 
In the malarial infected (Tumor-bearing) mice, the proportion and maturation of DCs along with CD11C 
(Integrin) was analyzed within the lymph node and it was reported that the percentage of DCs + CD11C was 
increased due to the antitumor activity and enhancement in immune response at the earlier stage.  
The expression of clusters of differentiation (CD80 and CD86) located on the dendritic cells was also 
upregulated due to increase in CD11C and DCs. That change was reported not to be found in uninfected tumor 
LLC cells that might be due to the suppression of immune system. The functions of DCs (tumor-specific T-cells 
recruitment and cross-priming) were checked whether they are affected with the enhancement in dendritic cells 
due to malarial infection.[38] Hence, the LLC-MUC1 cell line was analyzed by enzyme-linked immunospot 
(ELISPOT) for the production of TAA-specific granzyme B and IFN-c and significant increment was reported. 
 
Activation of Cell-Mediated Immunity 
The significant increase in the number of helper T-cells (CD4+) and Cytotoxic T-cells (CD8+) and their 
accumulation was also noticed within the tumor cells due to malarial infection that was confirmed by 
comparison. Hence, the cytotoxicity was also increased due to activity of increased cytotoxic T-cells. Likewise, 
the increased production of IFN-c that was specific to mucin-1 from the plasmodium infected LLC-MUC1 cell 
line took place in the spleen along with granzyme B-secreting cells and also showed systemic antitumor 
immunity. Proliferation of tumor-specific T-cells and TAA-specific proliferative ability was found to be 
increased due to malaria parasite infection in tumor cells that was responsible for the induction of systemic 
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antitumor immune response. 
Induction of Cytotoxicity in Natutal Killer Cells  
The cytotoxic activity of natural killer cells is included in adaptive immunity after the invasion of an antigen 
withn body following innate immunity confronted by the cytokines and Th1-type lymphocytes production i.e. 
TNF-α and IFN-c. They usually respond rapidly but in case of tumor (LLC), the host immune system had been 
compromised so no such action was happening.[39] But with the malarial infection, the rapid increase in the TNF-
α and IFN-c production levels was observed right after three days from the infection. Due to which potential 
enchancement in lytic activity of NK-cells was reported. Though the NK-cells percentage in the plasmodium 
infected LLC cells is similar to that of the uninfected tumor cells but the major difference is in their functioning 
and the increase in granzyme B producing NK-cells within the infected tumor tissue was also examined.  
Hence, the outcomes confirmed the role of plasmodium in the activation and elicitation of innate immune 
response within the suppressed tumor cells and as a result of that the enhanced functioning of NK-cells showed 
higher cytotoxicity to combat the tumor growth. 
 
Plasmodium as an Adjuvant Vaccine 
Adjuvants are the potent additives that play a vital role in the stimulation of immune response caused by antigens 
present in vaccine and persistence of long-lasting after effects. Several molecules found within the plasmodium 
parasite can be used in the development of an effective vaccine by acting as successful component i.e. 
adjuvant.[30] For the evaluation of the plasmodium components whether they perform successfully as an adjuvant 
in a vaccine or not, plasmodium infected LLC cells were injected with either DNA vaccines (pcDNAhMUC1 
and pcDNA3.1) to check the effect of plasmodium + DNA vaccine and the plain DNA vaccine over the tumor 
cells.  
It was proved by the outcomes that the combination of DNA vaccine and plasmodium for treatment caused 
the synergistic effect in the tumor growth inhibition and prolonged the survival period. Hence, it was reported 
that the plasmodium can be used as a novel adjuvant for facilitation in assistance of tumor-specific antitumor 
immunity. 
Immunotherapy have attracted the attention of all the scientists by playing a vital role in the cancer 
treatment that had been a major health issue for decades and neither any other therapeutic strategy nor the 
surgery was oftenly found to be that much successful and effective. The immunotherapy recovers suppressed 
immune response of the tumor host with the help of certain specific and non-specific immune stimulants. 
Conventional bio-immunoadjuvants like diphtheria, BCG and non-specific interventions including for 
stimulation of immune system i.e. TNF-α, IFN-α and IL-2 that induce the inflammatory cells accumulation and 
Th1 type cytokines production which shows a significant positive effect over the tumor cells and simultaneously 
helps in the treatment.[7] Whereas, the issue is with their immunity stimulation ability i.e. induce weak immune 
response, short-lasting and formation of defective memory cells. Hence, no desirable response was acquired by 
conventional clinical therapeutics unlike, certain recently developed pathogen-based immunotherapy.[40]  
Table 4: Comparison between Conventional and Plasmodium-infected Adjuvants 
Conventional adjuvants injected LLC Cells Plasmodium-infected LLC cells 
 Weak Immune Response 
 Short-Lived 
 Production of Defective Memory Cells 
 Production of Non-tumor Specific Abs 
 Suppressed Immune System 
 Strong and Tumor-Specific Immune Response 
 Long-Lasting 
 Production of Perfect Memory Cells 
 Polyclonal Activation Induction 
 Proliferation of Lymphocytes 
 
Cancer Treatment by GAG-Binding Malaria Protein 
With the invasion of Plasmodium falciparum in host body, it was examined that the parasite targets the 
erythrocytes (RBCs) at the first and starts to replicate within them. As they are now present within body, hence, 
they turns susceptible to the other RBCs as well and gets anchored to the particular cell receptors present in the 
vasculature of the host.[41] The protein that helped in the anchorage was found to be VAR2CSA, it carries out the 
binding of RBCs to placental syncytiotrophoblasts.[42] Placental malaria pathogenesis is the major event in which 
VAR2CSA interacts with the different type of chondroitin sulfate (CS) and glycosaminoglycan (GAG) polymer, 
collectively known as CSA.[43] The CS-binding site of VAR2CSA have a 2x domian of DBL (Duffy binding 
ligand) with some interdomain (ID) flanking regions. The very domain interacts CS by significant specificity as 
well as affinity.[44] 
By thorough examination of plasmodium infected RBCs, it was observed that their interaction with CS 
oligosaccharides took place by 4-O-sulfated character.[45] The parasites having VAR2CSA protein only do 
anchor to CS present in placenta despite of that they do not interacts elsewhere within body[42] due to the 
distinctive CS subtype expression in placenta that was involved in cellular invasion and promotes rapid 
proliferation by being part of implantation phenomenon in placenta.[46] Because of these two characteristics 
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(Invasion and Proliferation) that are found similar in both plancenta and cancer, it was concluded that the similar 
CS may also play vital role in the treatment of cancer. Thats why, a recombinant protein of VAR2CSA (rVAR2), 
was produced for the targeting of cancerous cells of human.[41] With the malarial infection, some genes (FabB/F, 
UIS3 and UIS4) starts to express within the RBCs at their pre-erythrocytic stage as they play an important role in 
the growth of infection.[47] These genes were deleted from the host and the decline in infection growth was 
examined along with the infection avoidance.[48] 
The malaria from this pre-erythrocytic stage was defective and is known as ‘Genetically Attenuated 
Sporozoites’ (GAS). Later on, it was reported that GAS was involved in the stimulation of immune response (IR) 
as former mentioned.[49] It was concluded that these fluctuatuion could be proved beneficial in treating lung 
cancer.[50] Human cancerous cells exhibit the similar expressed Placantal-Like CS. The ability of placental cells 
is associated with their chrondroitin sulfate proteoglycan (CSPG) component[51] that maintains invasion of 
villous trophoblasts during implantation stage within uterine tissue and regulates the maximum proliferation 
rate.[46] These are the phenotypic expressions that are correlated among the placental and tumor cells. It was 
reported that while having a clinical trial 95% compatibility outcomes were obtained from recombinant rVAR2-
binding to the epithelial, mesenchymal and hematopoietic cancerous cell lines. This interation among rVAR2 
and cells was highly based upon the protein concentration and if competed by CSA, it might get blocked. 
Moreover, 13 nM is the KD-value of occurrence of higher affinity among C32 melanoma cells and rVAR2-
binding. On the other hand, VAR2CSA-secreting malarial infected RBCs were achored over surface of C32 cell 
line. This is the major key step that could be restricted by purified CSA.  
ELISA and flow cytometry assays of the rVAR2-CSA were performed in order to evaluate the specificity 
with C32 cells.[41] Only the human cancerous and placental trophoblast cells can produce such distinguished CS 
that can specifically be detected by VAR2CSA. The CSA-biosynthesis takes place with the involvement of 
several enzymes.[52]  
 
Malarial Genetically Attenuated Sporozoites as Potent Cancer Vaccine 
The application of genetically attenuated sporozoites (GAS) of malaria for the development of a potential 
vaccine in order to elicit immunization have been considered as an attractive alternative approach. Effect of GAS 
on the tumor growth was determined and the tumor-specific immunization was induced within tumor cells. After 
14-days, the significant suppression in tumor growth was observed by measuring and comparing of the weights 
of tumor samples before and after particular time interval and the improvement in their survival period was also 
observed. This anti-cancer effect of GAS was studied thoroughly and it was acknowledged that the components 
of 1st line of defense of innate immunity against metastatic invasion that activates the signaling pathway for the 
production of cytokines like IL-12/6, TNF-α and IFN-γ were enhanced for provoking immediate immune 
response.[53] By flow cytometry, peripheral blood mononuclear cells (PBMCs) were analyzed and the number of 
production levels of both T-lymphocytes (CD4+ and CD8+) were increased due to the application of genetically 
attenuated sporozoites (GAS).  
 
Plasmodium as Delivery Vector in Vaccine Development  
Most of the conventional vaccine vectors have been used intensively whereas, most of them successfully induces 
the cellular mediated immune response but their major drawback was that the induced immunity did not last for 
long, it was short-lived. Therefore, some other protozoans have also been studied after working on plasmodium 
such as, Toxoplasmosis gondii[54] and Trypanosoma cruzi.[55] For the development of a successful and effective 
antigen based tumor vaccine, a suitable delivery vector is needed.[56]  
Jiang et al. Have worked previously on the plasmodium parasite as a delivery vector in order to develop an 
effective conceptual vaccine against human immunodeficiency virus (HIV) and it expressed the antitumor effect 
within mouse model while testing.[57] Likewise, the plasmodium has been used as a delivery vector against a 
hepatocellular carcinoma (HCC) cancer type in a vaccine and showed significant results. The tumor growth that 
was inhibited due to plasmodium was the result of induced immune mechanisms. 
A comparison among the Th1 and Th2-type cytokines was performed with and without the introduction of 
plasmodium into tumor cells and it was examined that the suppressed Th1-type cytokines (TNF-α, IFN-γ and IL-
2) started to increased in number and played a vital role in provoking immune response[58] whereas, the Th2-type 
cytokines (IL-13, IL-5 and IL-4) remained unaffected and no change in the production rate was recorded.[59] The 
cell-mediated immunity due to activity of cytotoxic T-lymphocytes (CD8+) was provoked in both of the stages 
of plasmodium life cycle i.e. in blood (Pre-erythrocytic stage) as well as in liver (Exo-erythrocytic stage) within 
the infected host exhibiting tumor.[60] Plasmodium can be used as a delivery vector for the successful expression 
of ectopic tumor antigens at the pre-erythrocytic stage of infection. Within the duration of 2-3 weeks from the 
infection, the parasitemia within blood reaches upto 50 percent and starts to cure itself within another 2 weeks. 
Hence, this prolonged period for the continuous and gradual release of parasites is standardized for inducing the 
immunization. It is reported that the expression of GPC3 protein within parasities is similar to the tumor protein 
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that regulates growth and proliferation of tumor cells and is responsible for the initiation of GPC-3 (TAA) 
specific immunity by the Cytotoxic T-lymphocytes (CTLs). It has been observed that major histocompatibility 
complex class I (MHC-I) is not present in the mature RBCs as well as immature infected RBCs (erythroblasts) 
thats why the association with phagocytes is required which might be the cause of inducing the immune 
responses by CD8+ T-cells that are MHC-I restricted.[60] Hence, the induction of CD8+ CTL-based immune 
response is independent of the infected erythroblasts. It has been further studied that the malaria parasite at pre-
erythrocytic stage induces CD8+ T-lymphocytes that are produced in response of antigens expressed by the 
parasite and are regulated by CD8α+ DCs.[61] The infection caused by Plasmodium falciparum and Plasmodium 
vivax was examined to be more likely in reticulocytes.[62] The changes in physiological and immunological 
processes due to plasmodium experienced in mice are supposed to be the similar within humans that could be of 
immense significance and puropose while treating the any kind of tumor.  
According to the previous hypothesis, it was assumed that the activation of CD4+ Th1-type-based immune 
reponse takes place at the first which later on triggers strong and lost-lasting CTL that is GPC-specific. A 
vaccine was designed consisting of plasmodium and GPC3 antigen that enhances the immunological processes 
of the host in order to counteract tumor cells growth. Indeed it may suppress the growth of tumor cells but can 
not eliminate these cells completely. That incomplete elimination was discovered to be because of small fraction 
of GPC3-antigen expressing tumor cells. It was concluded that a novel immunotherapy for the treatment of 
cancer was developed that involve use of plasmodium parasite as a delivery vector for the expression of tumor-
associated antigens (TAA) that would ultimately elicit the tumor-suppressed immune response. The 
immunomodulation of the immune system would be outcome of action of this vaccine. By experimental trial, the 
prolonged survival period as well as the enhanced immune system was reported within the mice models. Hence, 
the attenuated parasites as well as their attenuated sporozoites can be used as live vectors in vaccine 
development.[63] 
 
GAS induced Immunization  
Innate and adaptive immunity are the two major lines of defenses in the immune system of an organism. Innate 
immune system is usually the general and resistant for all the antigens whereas, adaptive is variable and antigen-
specific that regulates the immunity. For the activation of adaptive immune system, signals from the innate 
immune system are needed which shows that the innate immune system regulates the adaptive immune 
system.[64] The innate immunity in the tumor affected patients was immunomodulated by the introduction of 
attenuated sporozoites of plasmodium that stimulates the production of secretions of humoral immunity i.e. IL-
12, IL-6, TNF-α and IFN-γ within the three days of GAS insertion. These cytokines are the part of humoral 
immunity of innate immune system that are required for the induction of specific T-lymphocytes production that 
would result in activation of adaptive immunity and shows antitumor immune response.[65] Such immunization 
results in the strong adaptive immune response that would be cellular with the help of T-lymphocytes activity 
and proliferation against tumor cells.[49] It has been reported that genetically attenuated sporozoites (GAS) 
induced systemin immunity lasts for a long time interval and also produces memory cells.   
 
Immunosuppression by Tumor and Tumor-Specific Immune Response Provoked by Malaria 
Immunosurveillance is the mechanism of the scaning and monitoring of entire body for the detection of 
neoplastic or malignant cells that express particular tumor antigens. After recognition of such cells, the immune 
system of body takes it as a foreign particle or antigen and tries to destroy them.[66] In contrast to this, tumor cells 
exhibit the capability of suppressing the host immune system (immunosuppression) by activating immunological 
brakes or inhibitory feedback loopsor (Figure 1). Another function of these immunological brakes is avoidance 
of auto-immune disorders, creating barriers for activation of T-cells and tumor rejection.[67] Hence, the recovery 
of host immune response from the tumor induced immunosuppression and tolertogenic status for the cancer 
therapeutics is convenient.  
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Fig. 1: Immunosuppression Induced by Tumor 
There are various similar characteristics among parasites and cancer types as both of them 
weakens/suppresses the host immun system, harms at cellular, tissue or organ levels, develops inside the host 
and may metastasize at other locations within host.[68] It has been reported that avoidance of immunosurveillance 
and interation with innate immune system is acquired by the both (Parasites and Cancer cells) for the sake of 
development of their successful colonization. Therefore, due to this resemblance, the application of anti-parasitic 
drug have been assumed as advantageous in treatment of cancer as it may also act as anti-cancer drug.[69] 
Likewise, it has been studied that parasites might show antitumor activity by inducing immunomodulation 
(Figure 2).[54] 
 
Fig. 2: Immunomodulation Induced by Plasmodium 
 
Limitations of Plasmodium Immunotherapeutic Vaccine 
It has been acknowledged that most of the trials that have been performed were on rodents that shows ofcourse 
great similarity with human but certain complications were observed such as, there was no fever suffering 
(Hyperthermia) due to malaria in rodents unlike human[70] and the antitumor effects are more long-lasting in 
rodents, upto a month, which illustrates that infectious period is directly proportional to the effect on tumor 
growth inhibition. While the benign malaria in human was observed to cause hyperthermia at acute phase and 
the malaria parasite could survie for years in chronic stages if the treatment is not provided.[71] 
 
Current Status and Future Considerations 
The Plasmodium parasite has been used as the vaccine component due to its antitumor activity by resembling 
with cancer in characteristics and antigens in certain clinical trials. Certain other protozoans have also been 
studied after this therapeutic breakout of plasmodium and some of them have also been found as potential 
vectors and adjuvants for the vaccine development. But the research does not stops, scientists keep on digging 
the most advanced strategies for the ease in the treatment of health disasters like cancer in order to control its 
high mortality rate and protect the human health. Though the use of microbes in vaccine development is a 
traditional strategy by the process of attenuation but the plasmodium was used for the first time and its incredible 
antitumor effects have been observed. In near future, it is being anticipated that this immunotherapeutic agent 
would dominate other cancer treating strategies due to its higher efficiency as well as the biosecurity due to 
targeted treatment. The research on this approach regarding biotechnological applications have also been under 
processing as it’s the era of bionanotechnology. 
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